GLP-1 receptor agonists, originally used for treating type 2 diabetes, are increasingly studied as potential therapies for Parkinson's disease (PD). These agents have shown promise in preclinical and clinical studies for their ability to restore dopamine levels, inhibit dopaminergic loss, reduce neuronal degeneration, and alleviate both motor and non-motor symptoms of PD. Research indicates a potential link between PD and type 2 diabetes, with shared pathophysiological mechanisms involving the gut-brain axis, insulin resistance, and neuroinflammation. GLP-1 receptor agonists may offer neuroprotective effects by modulating inflammation, oxidative stress, mitochondrial function, and protein folding. Preclinical studies in animal models demonstrate that these drugs can protect dopaminergic neurons and improve motor function. Clinical trials are ongoing, with some showing improvements in motor and cognitive functions in PD patients. However, variability in responses across different PD models and patient populations suggests the need for personalized treatment approaches. Future research should focus on understanding the mechanisms of action, optimizing drug delivery, and exploring combination therapies. GLP-1 receptor agonists may represent a new class of drugs that could modify disease progression in PD.GLP-1 receptor agonists, originally used for treating type 2 diabetes, are increasingly studied as potential therapies for Parkinson's disease (PD). These agents have shown promise in preclinical and clinical studies for their ability to restore dopamine levels, inhibit dopaminergic loss, reduce neuronal degeneration, and alleviate both motor and non-motor symptoms of PD. Research indicates a potential link between PD and type 2 diabetes, with shared pathophysiological mechanisms involving the gut-brain axis, insulin resistance, and neuroinflammation. GLP-1 receptor agonists may offer neuroprotective effects by modulating inflammation, oxidative stress, mitochondrial function, and protein folding. Preclinical studies in animal models demonstrate that these drugs can protect dopaminergic neurons and improve motor function. Clinical trials are ongoing, with some showing improvements in motor and cognitive functions in PD patients. However, variability in responses across different PD models and patient populations suggests the need for personalized treatment approaches. Future research should focus on understanding the mechanisms of action, optimizing drug delivery, and exploring combination therapies. GLP-1 receptor agonists may represent a new class of drugs that could modify disease progression in PD.